[Table/Fig-5]:
Immunofluorescence characteristics of cutaneous amyloidosis.
| Characteristics | Clinical diagnosis | Total (n=50) | |||
|---|---|---|---|---|---|
| MA* (n=35) | LA** (n=8) | BA† (n=7) | |||
| N (%) | N (%) | N (%) | N (%) | ||
| Deposit | Negative | 5 (14.29%) | 0 (0%) | 1 (14.29 %) | 6 (12%) |
| Amorphous | 24 (68.57%) | 8 (100%) | 6 (85.71%) | 38 (76%) | |
| Colloid | 2 (5.71%) | 0 (0%) | (0%) | 2 (4%) | |
| Oval | 4 (11.43%) | 0 (0%) | 0 (0%) | 4 (8%) | |
| Histopathological Site | Negative | 5 (14.29%) | 0 (0%) | 1 (14.29%) | 6 (12%) |
| Papillary Dermis | 30 (85.71%) | 8 (100%) | 6 (85.71%) | 44 (88%) | |
| Negative | 5 (14.29%) | 0 (0%) | 1 (14.29%) | 6 (12%) | |
| IgM>A>C3 | 15 (42.86%) | 2 (25%) | 0 (0%) | 17 (34%) | |
| Type of Immunoreactants | IgM>A>G>C3 | 2 (5.71%) | 2 (25%) | 0 (0%) | 4 (8%) |
| IgM>C3 | 9 (25.71%) | 2 (25%) | 6 (85.71%) | 17 (34%) | |
| IgM>G>C3 | 2 (5.71%) | 2 (25%) | 0 (0%) | 4 (8%) | |
| IgM>G>C3, Fibrinogen | 2 (5.71%) | 0 (0%) | 0 (0%) | 2 (4%) | |
*
MA-Macular Amyloidosis,
**
LA-Lichen Amyloidosis,
†
BA – Biphasic Amyloidosis